Reuters logo
BRIEF-AstraZeneca, Takeda collaborate to develop, commercialise MEDI1341 for Parkinson's disease
August 29, 2017 / 6:18 AM / a month ago

BRIEF-AstraZeneca, Takeda collaborate to develop, commercialise MEDI1341 for Parkinson's disease

Aug 29 (Reuters) - AstraZeneca Plc

* ASTRAZENECA AND TAKEDA ESTABLISH COLLABORATION TO DEVELOP AND COMMERCIALISE MEDI1341 FOR PARKINSON‘S DISEASE

* PARTIES ENTERS DEAL TO DEVELOP, COMMERCIALISE MEDI1341, ALPHA-SYNUCLEIN ANTIBODY CURRENTLY IN DEVELOPMENT AS POTENTIAL TREATMENT FOR PARKINSON‘S DISEASE Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below